Department of Medicine, Cardiovascular Division, Washington University in St. Louis, St. Louis, Missouri, USA.
Department of Medicine, Infectious Disease, Washington University School of Medicine, St. Louis, Missouri, USA.
J Virol. 2024 Sep 17;98(9):e0117924. doi: 10.1128/jvi.01179-24. Epub 2024 Aug 29.
Cardiovascular manifestations of coronavirus disease 2019 (COVID-19) include myocardial injury, heart failure, and myocarditis and are associated with long-term disability and mortality. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA and antigens are found in the myocardium of COVID-19 patients, and human cardiomyocytes are susceptible to infection in cell or organoid cultures. While these observations raise the possibility that cardiomyocyte infection may contribute to the cardiac sequelae of COVID-19, a causal relationship between cardiomyocyte infection and myocardial dysfunction and pathology has not been established. Here, we generated a mouse model of cardiomyocyte-restricted infection by selectively expressing human angiotensin-converting enzyme 2 (hACE2), the SARS-CoV-2 receptor, in cardiomyocytes. Inoculation of mice with an ancestral, non-mouse-adapted strain of SARS-CoV-2 resulted in viral replication within the heart, accumulation of macrophages, and moderate left ventricular (LV) systolic dysfunction. Cardiac pathology in this model was transient and resolved with viral clearance. Blockade of monocyte trafficking reduced macrophage accumulation, suppressed the development of LV systolic dysfunction, and promoted viral clearance in the heart. These findings establish a mouse model of SARS-CoV-2 cardiomyocyte infection that recapitulates features of cardiac dysfunctions of COVID-19 and suggests that both viral replication and resultant innate immune responses contribute to cardiac pathology.IMPORTANCEHeart involvement after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection occurs in multiple ways and is associated with worse outcomes in coronavirus disease 2019 (COVID-19) patients. It remains unclear if cardiac disease is driven by primary infection of the heart or immune response to the virus. SARS-CoV-2 is capable of entering contractile cells of the heart in a culture dish. However, it remains unclear how such infection affects the function of the heart in the body. Here, we designed a mouse in which only heart muscle cells can be infected with a SARS-CoV-2 strain to study cardiac infection in isolation from other organ systems. In our model, infected mice show viral infection, worse function, and accumulation of immune cells in the heart. A subset of immune cells facilitates such worsening heart function. As this model shows features similar to those observed in patients, it may be useful for understanding the heart disease that occurs as a part of COVID-19.
新型冠状病毒病 2019(COVID-19)的心血管表现包括心肌损伤、心力衰竭和心肌炎,并与长期残疾和死亡率相关。在 COVID-19 患者的心肌中发现了严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)RNA 和抗原,并且在细胞或类器官培养物中,人类心肌细胞容易受到感染。虽然这些观察结果提出了一种可能性,即心肌细胞感染可能导致 COVID-19 的心脏后遗症,但尚未确定心肌细胞感染与心肌功能障碍和病理学之间存在因果关系。在这里,我们通过在心肌细胞中选择性表达人类血管紧张素转换酶 2(hACE2),即 SARS-CoV-2 受体,生成了一种心肌细胞特异性感染的小鼠模型。用非小鼠适应性 SARS-CoV-2 祖先株接种 小鼠导致病毒在心脏内复制,巨噬细胞积累,左心室(LV)收缩功能中度障碍。该模型中的心脏病理学是短暂的,并随着病毒清除而消退。单核细胞迁移阻断减少了巨噬细胞的积累,抑制了 LV 收缩功能障碍的发展,并促进了心脏内的病毒清除。这些发现建立了一种 SARS-CoV-2 心肌细胞感染的小鼠模型,该模型再现了 COVID-19 中心律失常的特征,并表明病毒复制和由此产生的固有免疫反应均有助于心脏病理学。
重要性
严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)感染后心脏受累的发生方式有多种,与 COVID-19 患者的预后较差相关。心脏疾病是否由心脏的原发性感染或对病毒的免疫反应驱动仍不清楚。SARS-CoV-2 在培养皿中的心肌细胞中能够进入。然而,尚不清楚这种感染如何影响体内心脏的功能。在这里,我们设计了一种只有心肌细胞才能被 SARS-CoV-2 株感染的小鼠,以研究心脏感染与其他器官系统分离的情况。在我们的模型中,感染的小鼠显示出病毒感染、心脏功能恶化和免疫细胞在心脏中的积累。免疫细胞的一部分促进了这种心脏功能恶化。由于该模型显示出与患者观察到的特征相似,因此对于理解 COVID-19 发生的心脏病可能是有用的。